{"id":543885,"date":"2021-05-19T22:46:01","date_gmt":"2021-05-19T22:46:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=543885"},"modified":"2021-05-19T22:46:01","modified_gmt":"2021-05-19T22:46:01","slug":"eosinophilic-esophagitis-market-industry-analysis-drugs-key-companies-by-delveinsight-takeda-sanofi-regeneron-pharmaceuticals-bristolmyers-squibb-astrazeneca-and-others","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/eosinophilic-esophagitis-market-industry-analysis-drugs-key-companies-by-delveinsight-takeda-sanofi-regeneron-pharmaceuticals-bristolmyers-squibb-astrazeneca-and-others_543885.html","title":{"rendered":"Eosinophilic Esophagitis Market: Industry Analysis, Drugs, Key Companies by DelveInsight | Takeda, Sanofi, Regeneron Pharmaceuticals, Bristol-Myers Squibb, AstraZeneca and Others"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1621406390.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Eosinophilic Esophagitis Market: Industry Analysis, Drugs, Key Companies by DelveInsight | Takeda, Sanofi, Regeneron Pharmaceuticals, Bristol-Myers Squibb, AstraZeneca and Others\" src=\"https:\/\/www.abnewswire.com\/uploads\/1621406390.jpeg\" alt=\"Eosinophilic Esophagitis Market: Industry Analysis, Drugs, Key Companies by DelveInsight | Takeda, Sanofi, Regeneron Pharmaceuticals, Bristol-Myers Squibb, AstraZeneca and Others\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/p>\n<div class=\"quotes\">\n<div>Eosinophilic Esophagitis Market<\/div>\n<\/div>\n<\/div>\n<p style=\"text-align: justify;\">DelveInsight&#8217;s <strong>&#8220;<\/strong><strong>Eosinophilic Esophagitis (EoE) Market<\/strong><strong>&#8220;<\/strong> report provides a thorough comprehension of the Eosinophilic Esophagitis, historical and forecasted epidemiology, and the Eosinophilic Esophagitis market trends in the 7MM [the United States, EU5 (Germany,&nbsp;Spain,&nbsp;Italy,&nbsp;France, and&nbsp;United Kingdom) and&nbsp;Japan]. The Eosinophilic Esophagitis market report also proffers an analysis of the current Eosinophilic Esophagitis treatment algorithm\/practice, market drivers, market barriers, and unmet medical needs.&nbsp;<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Some of the imperative takeaways of the&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/eosinophilic-esophagitis-market?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">Eosinophilic Esophagitis Market Research Report<\/a>:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>A slew of companies such as&nbsp;<strong>EsoCap AG, Arena Pharmaceutical, GlaxoSmithKline, Dr Falk Pharma GmbH, Takeda, Regeneron Pharmaceuticals, Sanofi, Bristol-Myers Squibb, Ellodi Pharmaceuticals, AstraZeneca, Allakos<\/strong>, and others are developing therapies to influence Eosinophilic Esophagitis treatment outlook.&nbsp;<\/li>\n<\/ul>\n<ul style=\"text-align: justify;\">\n<li>Increased understanding of the clinical manifestations of the disease in conjunction with improved diagnosis and evolving treatment landscape will boost the Eosinophilic Esophagitis market landscape scenario..&nbsp;<\/li>\n<li>The US FDA has granted&nbsp;<strong>priority review, breakthrough therapy designation, and orphan designation to Budesonide Oral Suspension (BOS)<\/strong>&nbsp;for the EoE treatment.&nbsp;<\/li>\n<li>In the Phase II study,&nbsp;<strong>RPC4046<\/strong>&nbsp;demonstrated positive results. Currently,&nbsp;<strong>Bristol-Myers Squibb<\/strong>&nbsp;is conducting a&nbsp;<strong>Phase III<\/strong>&nbsp;clinical study to evaluate the efficacy and safety of&nbsp;<strong>CC-93538&nbsp;<\/strong>in adult and adolescent participants with the indication.<\/li>\n<li><strong>APT-1011&nbsp;<\/strong>has received&nbsp;<strong>orphan drug designation<\/strong>&nbsp;from the<strong>&nbsp;FDA<\/strong>. It is currently in&nbsp;<strong>Phase III&nbsp;<\/strong>development&nbsp;<strong>(FLUTE II),<\/strong>&nbsp;following the successful completion of its phase II study (FLUTE I) in 2019.&nbsp;<\/li>\n<li><strong>Benralizumab&nbsp;<\/strong>is currently approved under the brand name Fasenra as an add-on maintenance treatment of severe asthma in patients aged &ge;12 years and with an eosinophilic phenotype. Now, it is being evaluated in the<strong>&nbsp;Phase III&nbsp;<\/strong>study for the treatment of EoE.&nbsp;<\/li>\n<li>Currently,&nbsp;<strong>Lirentelimab&nbsp;<\/strong>is being evaluated in&nbsp;<strong>Phase II\/III&nbsp;<\/strong>study for the Eosinophilic Esophagitis treatment in adult and adolescent subjects. The US FDA has granted&nbsp;<strong>orphan drug designation to antolimab<\/strong>&nbsp;for the treatment of EoE.&nbsp;<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Get a sample copy of this report:&nbsp;<\/strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/eosinophilic-esophagitis-market?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\" target=\"_blank\">Eosinophilic Esophagitis Market Size Landscape<\/a><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Eosinophilic Esophagitis<\/strong> (EoE) represents a chronic, local immune-mediated oesophagal disease, characterized clinically by symptoms related to oesophagal dysfunction and histologically by eosinophil-predominant inflammation.&nbsp;<\/p>\n<p style=\"text-align: justify;\">As per the estimates by DelveInsight, the&nbsp;total diagnosed Eosinophilic Esophagitis prevalent cases&nbsp;in 2020 were&nbsp;<strong>547,924<\/strong>&nbsp;cases. The highest prevalent cases were observed in&nbsp;the United States, accounting for approximately&nbsp;<strong>58%<\/strong>&nbsp;of the total cases.&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Eosinophilic Esophagitis Treatment Market&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\">The Eosinophilic Esophagitis treatment involves&nbsp;Drugs, Diet, and Dilation. The first two components, which involve the use of proton pump inhibitors (PPIs), corticosteroids, immunosuppressant&#8217;s, and empirical diets or guided food elimination based on allergy tests, are more useful in the initial phases. In contrast, endoscopic dilation is reserved for oesophagal strictures.&nbsp;<\/p>\n<p style=\"text-align: justify;\">Three dietary approaches for the management of EoE have emerged: the elemental diet, empiric dietary restrictions, and targeted dietary restrictions based on allergy testing.<\/p>\n<p style=\"text-align: justify;\">PPIs are helpful as a first-line treatment for EoE patients. This therapy reduces acid production in the stomach and can reduce oesophagal inflammation. PPIs are recommended to be administered twice daily and continued for a minimum 2-month course after oesophagal eosinophilia is discovered. Afterwards, a repeat endoscopy with biopsies is performed to assess for persistent eosinophilic infiltration.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/eosinophilic-esophagitis-market?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\" target=\"_blank\">Eosinophilic Esophagitis Emerging Therapies<\/a><\/strong><strong> Along with Key Players<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Budesonide Oral Suspension: Takeda<\/li>\n<li>Dupilumab: Regeneron Pharmaceuticals\/Sanofi<\/li>\n<li>Cendakimab: Bristol-Myers Squibb<\/li>\n<li>APT-1011: Ellodi Pharmaceuticals<\/li>\n<li>Benralizumab: AstraZeneca<\/li>\n<li>Lirentelimab: Allakos&nbsp;<\/li>\n<li>And several others.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Final thoughts on&nbsp;<\/strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/eosinophilic-esophagitis-market?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\" target=\"_blank\">Eosinophilic Esophagitis Market Growth<\/a>&nbsp;<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">Eosinophilic Esophagitis Market Drivers&nbsp;such as<strong>&nbsp;increasing awareness, the emergence of non-invasive modalities, identification of biomarkers, development of animal models<\/strong>&nbsp;are responsible for Market Growth. In contrast,&nbsp;<strong>Eosinophilic Esophagitis Market Barriers&nbsp;<\/strong>such as&nbsp;<strong>high cost of treatment, lack of multidisciplinary management, and lack of optimal endpoint for treatment&nbsp;<\/strong>will nosedive the market size.&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Request for a Webex demo of the report @&nbsp;<\/strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/eosinophilic-esophagitis-market?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\" target=\"_blank\">Eosinophilic Esophagitis Treatment Market Size<\/a><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Table of Contents<\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<table border=\"1\" cellspacing=\"0\" cellpadding=\"0\">\n<tbody>\n<tr>\n<td valign=\"bottom\">\n<p>1<\/p>\n<\/td>\n<td valign=\"bottom\">\n<p>Eosinophilic Esophagitis (EoE) Key Insights&nbsp;<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"bottom\">\n<p>2<\/p>\n<\/td>\n<td valign=\"bottom\">\n<p>Eosinophilic Esophagitis Report Introduction<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"bottom\">\n<p>3<\/p>\n<\/td>\n<td valign=\"bottom\">\n<p>Eosinophilic Esophagitis Market Overview at a Glance<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"bottom\">\n<p>4<\/p>\n<\/td>\n<td valign=\"bottom\">\n<p>Eosinophilic Esophagitis Patient Split at a Glance<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"bottom\">\n<p>5<\/p>\n<\/td>\n<td valign=\"bottom\">\n<p>Executive Summary of Eosinophilic Esophagitis&nbsp;<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"bottom\">\n<p>6<\/p>\n<\/td>\n<td valign=\"bottom\">\n<p>Eosinophilic Esophagitis Disease Background and Overview<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"bottom\">\n<p>7<\/p>\n<\/td>\n<td valign=\"bottom\">\n<p>EoE Treatment<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"bottom\">\n<p>8<\/p>\n<\/td>\n<td valign=\"bottom\">\n<p>Guidelines for Management of EoE&nbsp;<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"bottom\">\n<p>9<\/p>\n<\/td>\n<td valign=\"bottom\">\n<p>Eosinophilic Esophagitis Epidemiology and Patient Population&nbsp;<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"bottom\">\n<p>9.1<\/p>\n<\/td>\n<td valign=\"bottom\">\n<p>The United States<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"bottom\">\n<p>9.2<\/p>\n<\/td>\n<td valign=\"bottom\">\n<p>EU5 Countries<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"bottom\">\n<p>9.2.1<\/p>\n<\/td>\n<td valign=\"bottom\">\n<p>Germany<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"bottom\">\n<p>9.2.2<\/p>\n<\/td>\n<td valign=\"bottom\">\n<p>France<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"bottom\">\n<p>9.2.3<\/p>\n<\/td>\n<td valign=\"bottom\">\n<p>Italy<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"bottom\">\n<p>9.2.4<\/p>\n<\/td>\n<td valign=\"bottom\">\n<p>Spain<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"bottom\">\n<p>9.2.5<\/p>\n<\/td>\n<td valign=\"bottom\">\n<p>The United Kingdom<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"bottom\">\n<p>9.3<\/p>\n<\/td>\n<td valign=\"bottom\">\n<p>Japan<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"bottom\">\n<p>10<\/p>\n<\/td>\n<td valign=\"bottom\">\n<p>Organizations contributing toward the fight against EoE<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"bottom\">\n<p>11<\/p>\n<\/td>\n<td valign=\"bottom\">\n<p>EoE&nbsp;Patient Journey<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"bottom\">\n<p>12<\/p>\n<\/td>\n<td valign=\"bottom\">\n<p>Case Report<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"bottom\">\n<p>13<\/p>\n<\/td>\n<td valign=\"bottom\">\n<p>Eosinophilic Esophagitis Marketed Drug<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"bottom\">\n<p>13.1<\/p>\n<\/td>\n<td valign=\"bottom\">\n<p>Jorveza: Dr Falk Pharma GmbH<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"bottom\">\n<p>14<\/p>\n<\/td>\n<td valign=\"bottom\">\n<p>Eosinophilic Esophagitis Emerging Drugs<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"bottom\">\n<p>14.1<\/p>\n<\/td>\n<td valign=\"bottom\">\n<p>Budesonide Oral Suspension: Takeda<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"bottom\">\n<p>14.2<\/p>\n<\/td>\n<td valign=\"bottom\">\n<p>Dupilumab: Regeneron Pharmaceuticals\/Sanofi<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"bottom\">\n<p>14.3<\/p>\n<\/td>\n<td valign=\"bottom\">\n<p>Cendakimab: Bristol-Myers Squibb<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"bottom\">\n<p>14.4<\/p>\n<\/td>\n<td valign=\"bottom\">\n<p>APT-1011: Ellodi Pharmaceuticals<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"bottom\">\n<p>14.5<\/p>\n<\/td>\n<td valign=\"bottom\">\n<p>Benralizumab: AstraZeneca<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"bottom\">\n<p>14.6<\/p>\n<\/td>\n<td valign=\"bottom\">\n<p>Lirentelimab: Allakos<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"bottom\">\n<p>15<\/p>\n<\/td>\n<td valign=\"bottom\">\n<p>Other Promising Therapies<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"bottom\">\n<p>15.1<\/p>\n<\/td>\n<td valign=\"bottom\">\n<p>ESO-101: EsoCap AG<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"bottom\">\n<p>15.2<\/p>\n<\/td>\n<td valign=\"bottom\">\n<p>Etrasimod: Arena Pharmaceutical<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"bottom\">\n<p>15.3<\/p>\n<\/td>\n<td valign=\"bottom\">\n<p>Mepolizumab: GlaxoSmithKline<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"bottom\">\n<p>16<\/p>\n<\/td>\n<td valign=\"bottom\">\n<p>7MM Eosinophilic Esophagitis Market Analysis<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"bottom\">\n<p>16.1<\/p>\n<\/td>\n<td valign=\"bottom\">\n<p>The United States Eosinophilic Esophagitis Market Size<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"bottom\">\n<p>16.2<\/p>\n<\/td>\n<td valign=\"bottom\">\n<p>EU-5 Eosinophilic Esophagitis Market Size<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"bottom\">\n<p>16.2.1<\/p>\n<\/td>\n<td valign=\"bottom\">\n<p>Germany Market Size<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"bottom\">\n<p>16.2.2<\/p>\n<\/td>\n<td valign=\"bottom\">\n<p>France Market Size<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"bottom\">\n<p>16.2.3<\/p>\n<\/td>\n<td valign=\"bottom\">\n<p>Italy Market Size<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"bottom\">\n<p>16.2.4<\/p>\n<\/td>\n<td valign=\"bottom\">\n<p>Spain Market Size<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"bottom\">\n<p>16.2.5<\/p>\n<\/td>\n<td valign=\"bottom\">\n<p>The United Kingdom Market Size<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"bottom\">\n<p>16.3<\/p>\n<\/td>\n<td valign=\"bottom\">\n<p>Japan&nbsp;Eosinophilic Esophagitis Market Size<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"bottom\">\n<p>17<\/p>\n<\/td>\n<td valign=\"bottom\">\n<p>KOL Views<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"bottom\">\n<p>18<\/p>\n<\/td>\n<td valign=\"bottom\">\n<p>Eosinophilic Esophagitis Market Drivers<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"bottom\">\n<p>19<\/p>\n<\/td>\n<td valign=\"bottom\">\n<p>Eosinophilic Esophagitis Market Barriers<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"bottom\">\n<p>20<\/p>\n<\/td>\n<td valign=\"bottom\">\n<p>SWOT Analysis of Eosinophilic Esophagitis<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"bottom\">\n<p>21<\/p>\n<\/td>\n<td valign=\"bottom\">\n<p>Eosinophilic Esophagitis Unmet Needs<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"bottom\">\n<p>22<\/p>\n<\/td>\n<td valign=\"bottom\">\n<p>Appendix<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"bottom\">\n<p>23<\/p>\n<\/td>\n<td valign=\"bottom\">\n<p>DelveInsight Capabilities<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"bottom\">\n<p>24<\/p>\n<\/td>\n<td valign=\"bottom\">\n<p>Disclaimer<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"bottom\">\n<p>25<\/p>\n<\/td>\n<td valign=\"bottom\">\n<p>About DelveInsight<\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Browse full report with detailed TOC with charts, figures, tables @&nbsp;<\/strong>Eosinophilic Esophagitis Market Share Report<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>About&nbsp;DelveInsight<\/strong><br \/> DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56434.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Ankit Nigam<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=eosinophilic-esophagitis-market-industry-analysis-drugs-key-companies-by-delveinsight-takeda-sanofi-regeneron-pharmaceuticals-bristolmyers-squibb-astrazeneca-and-others\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +19193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Albany<br \/><strong>State:<\/strong> New York<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/report-store\/eosinophilic-esophagitis-market\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/report-store\/eosinophilic-esophagitis-market<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/report-store\/eosinophilic-esophagitis-market\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=eosinophilic-esophagitis-market-industry-analysis-drugs-key-companies-by-delveinsight-takeda-sanofi-regeneron-pharmaceuticals-bristolmyers-squibb-astrazeneca-and-others\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Eosinophilic Esophagitis Market DelveInsight&#8217;s &#8220;Eosinophilic Esophagitis (EoE) Market&#8220; report provides a thorough comprehension of the Eosinophilic Esophagitis, historical and forecasted epidemiology, and the Eosinophilic Esophagitis market trends in the 7MM [the United States, EU5 (Germany,&nbsp;Spain,&nbsp;Italy,&nbsp;France, and&nbsp;United Kingdom) and&nbsp;Japan]. The Eosinophilic &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/eosinophilic-esophagitis-market-industry-analysis-drugs-key-companies-by-delveinsight-takeda-sanofi-regeneron-pharmaceuticals-bristolmyers-squibb-astrazeneca-and-others_543885.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,417,406,423],"tags":[],"class_list":["post-543885","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Marketing-Sales","category-Pharmaceuticals-Biotech","category-Professional-Services"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/543885","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=543885"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/543885\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=543885"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=543885"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=543885"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}